International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationRisk Factors for Pericardial Effusion in Inoperable Esophageal Cancer Patients Treated With Definitive Chemoradiation Therapy
Introduction
Many malignant tumors occurring in the thoracic region are treated routinely by means of radiotherapy (RT), often in combination with chemotherapy. Although advances in multiagent chemotherapy and RT have led to increased survival, this was made at the expense of increased toxicities 1, 2, 3. Reducing the risk of radiation injury to adjacent healthy organs could have a significant impact on patient outcome in clinical RT. In the treatment of patients with esophageal cancer, a significant portion of the heart may be unavoidably included in the planning target volume (PTV), especially in patients with distal esophageal cancer. Therefore, radiation-induced cardiac toxicities have been observed post-therapy. Cardiac toxicities include pericardial effusion (PCE), pericarditis, coronary artery disease, cardiomyopathy, valvular dysfunction, conduction abnormalities, and autonomic dysfunction (4). Previous reviews showed an incidence of PCE after RT in the range of 20–40%, and asymptomatic PCE is the most common cardiac side effect from radiation 5, 6.
Effects of RT on the heart were well documented in patients with breast cancer 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 and lymphoma 17, 18, 19, 20, 21, 22, 23, 24. However, results varied considerably across different institutions about which dosimetric factors were more important than the others 8, 11, 16, 20, 23, 24. Cardiac dose may be alarmingly high in patients with distal esophageal cancer; but with few published studies available 25, 26, radiation injury to the heart is not well understood in this cohort of patients. In particular, PCE in patients with esophageal cancer treated with definitive concurrent chemotherapy (CCT) and RT was not investigated to date.
The present study was undertaken to determine clinical and dosimetric risk factors influencing the risk of PCE in patients with esophageal cancer. Findings from this study may lead to better understanding of PCE and prevention of this toxicity in RT for patients with esophageal cancer.
Section snippets
Patient selection
This study was approved by an institutional review board, abiding regulations of the Health Insurance Portability and Accountability Act. We retrospectively reviewed medical and radiation records of all patients with inoperable esophageal cancer treated with definitive concurrent chemoradiation therapy without surgery from January 2000 to December 2003 in the Department of Radiation Oncology at the University of Texas M.D. Anderson Cancer Center, Houston, TX. The following criteria were used to
Results
A total of 101 patients met criteria for inclusion in this study. Patient characteristics are listed in Table 1. Median follow-up for the present cohort of patients was 8.4 months (range, 0.4–48.6 months). A total of 40.6% of patients (41 of 101 patients) had follow-up less than 6 months; 16.8% (17 of 101 patients), 6–12 months; 26.7% (27 of 101 patients), 13–24 months; and 15.9% (16 of 101 patients), longer than 24 months. Of this patient cohort, 25 patients underwent induction chemotherapy
Discussion
In this study, we investigated the pattern of onset for PCE and important factors that may influence its risk in patients with inoperable esophageal cancer treated with concurrent chemoradiation therapy. Inflammation of the pericardium and PCE are some of the most common acute cardiac toxicities in patients treated with chest irradiation. Table 4 lists previous studies of PCE, pericarditis, and other cardiac toxicities, especially in patients with esophageal cancer. Radiation dosage 5, 24, 25,
References (34)
- et al.
Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non–small cell lung carcinoma: Long-term results and associations with pathologic response
J Thorac Cardiovasc Surg
(2004) - et al.
Radiation-associated cardiovascular disease: Manifestations and management
Semin Radiat Oncol
(2003) - et al.
The incidence and functional consequences of RT-associated cardiac perfusion defects
Int J Radiat Oncol Biol Phys
(2005) - et al.
Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy
Radiother Oncol
(2002) - et al.
Cardiac avoidance in breast radiotherapy: A comparison of simple shielding techniques with intensity-modulated radiotherapy
Radiother Oncol
(2001) - et al.
Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: Preliminary results
Int J Radiat Oncol Biol Phys
(2001) - et al.
Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer
Radiother Oncol
(1998) - et al.
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
Blood
(2006) - et al.
Ischemic heart disease after mantlefield irradiation for Hodgkin's disease in long-term follow-up
Radiother Oncol
(1999) - et al.
Cardiac disease after chest irradiation for Hodgkin's disease: Incidence in 108 patients with long follow-up
Int J Cardiol
(1995)
Pericarditis and myocardial infarctions after Hodgkin's disease therapy
Int J Radiat Oncol Biol Phys
Fraction size and dose parameters related to the incidence of pericardial effusions
Int J Radiat Oncol Biol Phys
Long-term complications of treatment and causes of mortality after Hodgkin's disease
Semin Radiat Oncol
Chemoradiotherapy of non-small cell lung cancer
Expert Rev Anticancer Ther
Induction chemotherapy followed by radical local therapy for locally advanced non-small cell lung cancer
Semin Surg Oncol
Radiation-induced cardiomyopathy as a function of radiation beam gating to the cardiac cycle
Phys Med Biol
Cardiovascular effects of radiation therapy: Practical approach to radiation therapy-induced heart disease
Cardiol Rev
Cited by (158)
Dynamic changes in cardiac biomarkers in radiotherapy for oesophageal cancer and their correlations with cardiac radiation dosimetry
2024, Clinical and Translational Radiation Oncology
Presented at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), Philadelphia, PA, November 5–9, 2006.
Supported in part by the Radiological Society of North America Education and Research Foundation, a grant to “Teach the Teachers in Emerging Nations,” and a research grant from the National Cancer Institute (NCI-R01-CA074043-08A2).
Conflict of interest: none.